Later this year, the US Food and Drug Administration plans to expand its use of a new quality assessment platform to include not just generic drug applications but also active pharmaceutical ingredient drug master files (DMFs), and new drug applications (NDAs).
The agency last year used the Knowledge-Aided Assessment and Structured Application platform in reviewing more than 500 generic drug applications...